XNAS · Healthcare · Biotechnology
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | Q2 2026 | -0.03 | 0.04 | +233.33% | $77.5M | ✅ Beat | +1.03% | -6.01% | -13.99% |
| 2026-05-07 | Q1 2026 | -0.15 | -0.12 | +20.00% | $68.4M | ✅ Beat | +1.96% | -5.66% | +3.33% |
| 2026-02-26 |
| Q4 2025 |
| 0.41 |
| 0.45 |
| +9.76% |
| $92.9M |
| ✅ Beat |
| +1.62% |
| -9.77% |
| -22.13% |
| 2025-11-06 | Q3 2025 | -0.02 | 0.10 | +600.00% | $67.5M | ✅ Beat | — | — | — |
| 2025-07-31 | Q2 2025 | -0.04 | -0.01 | +75.00% | $63.2M | ✅ Beat | -6.52% | +3.46% | +4.06% |
| 2025-02-27 | Q4 2024 | 0.34 | 0.38 | +11.76% | $75.4M | ✅ Beat | +3.37% | -1.73% | -10.08% |
| 2024-11-07 | Q3 2024 | -0.05 | -0.02 | +60.00% | $57.9M | ✅ Beat | +7.94% | +5.42% | +12.65% |
| 2024-08-01 | Q2 2024 | -0.08 | -0.10 | -25.00% | $52.7M | ❌ Miss | +0.21% | -2.67% | +3.20% |
Showing last 8 quarters.